FDA Approves Subcutaneous Lecanemab for Maintenance Treatment in Early Alzheimer’s Disease: A Step Toward More Accessible Care

Highlight

• The FDA has approved a weekly 360 mg subcutaneous formulation of lecanemab (Leqembi Iqlik) for maintenance treatment of early Alzheimer’s disease (AD) after initial intravenous (IV) therapy.
• Subcutaneous dosing provides comparable clinical efficacy and biomarker effects to continued IV dosing but with significantly fewer systemic reactions and increased convenience.
• The safety profile for subcutaneous administration is consistent with prior data; local reactions are mild and manageable, and rates of amyloid-related imaging abnormalities (ARIAs) remain similar.
• This approval is heralded as a pivotal step toward more patient-friendly, potentially at-home Alzheimer’s treatment regimens enabling combination therapies.

Study Background and Disease Burden

Alzheimer’s disease is a progressive neurodegenerative disorder characterized by cognitive decline and functional impairment. Early stages include mild cognitive impairment (MCI) due to AD and mild dementia. Despite advances, disease-modifying treatments remain limited, and therapeutic delivery barriers pose challenges for patients and healthcare providers.

Lecanemab is a humanized monoclonal antibody that targets amyloid-beta (Aβ) protofibrils, aiming to reduce amyloid plaque burden—a hallmark pathology of AD. The intravenous (IV) formulation of lecanemab demonstrated efficacy in early AD patients, but IV administration every two weeks can be logistically burdensome, limiting treatment accessibility and patient adherence.

Developing a subcutaneous (SC) formulation aims to facilitate maintenance dosing, reduce systemic adverse events, lessen caregiver burden, and pave the way for more convenient multimodal therapeutic approaches.

Study Design

The safety and efficacy of subcutaneous lecanemab as a maintenance regimen were evaluated in the open-label extension of the phase 3 Clarity AD trial.

Patients with early AD (MCI or mild dementia due to AD) who had completed 18 months of lecanemab IV treatment at 10 mg/kg every two weeks were eligible to either continue IV infusions at a reduced frequency (10 mg/kg every 4 weeks) or switch to weekly 360 mg subcutaneous injections administered via the Leqembi Iqlik autoinjector.

Endpoints included maintenance of clinical and biomarker efficacy, safety profiles (including systemic and local reactions), and incidence of amyloid-related imaging abnormalities (ARIAs), an important safety concern with anti-amyloid immunotherapies.

Key Findings

Transitioning from IV to weekly subcutaneous maintenance dosing preserved the clinical benefits observed with continuous IV infusion. Patients demonstrated sustained disease-modifying effects over four years, assessed by cognitive measures and biomarker readouts related to amyloid load.

The safety profile of the subcutaneous route was favorable. Systemic reactions were markedly fewer with subcutaneous injections (<1%) compared to continued IV infusions (26%), a significant reduction likely reflecting the more gradual absorption and reduced peak plasma concentrations.

Local injection site reactions were reported in approximately 11% of patients receiving subcutaneous lecanemab; symptoms included mild to moderate redness, swelling, or itching, none of which interfered with ongoing treatment.

The incidence of ARIAs in the subcutaneous group was comparable to the IV-maintained cohort after 18 months. Notably, ARIAs typically manifested within the first six months of IV therapy initiation, indicating no increased risk with the subcutaneous maintenance approach.

Availability of the Leqembi Iqlik autoinjector in the United States is anticipated to commence on October 6, expanding access and convenience for patients.

Expert Commentary

Howard Fillit, MD, co-founder and chief science officer of the Alzheimer’s Drug Discovery Foundation, emphasized that transitioning to subcutaneous dosing aligns with trends in chronic disease management, akin to diabetes and GLP-1 receptor agonist therapies. He highlighted the potential to alleviate patient and caregiver burden by simplifying treatment logistics.

Dr. Fillit also noted that Alzheimer’s is a complex, multifactorial disease, suggesting the future of care will rely on precision combination therapies tailored by biomarker profiles. The subcutaneous formulation is a gateway to more versatile and patient-centered delivery methods that could accelerate this therapeutic evolution.

While the data to date are promising, longer-term real-world surveillance and additional studies exploring home administration feasibility and combination regimens will be important to optimize treatment paradigms.

Conclusion

The FDA’s approval of the subcutaneous formulation of lecanemab for maintenance treatment marks a significant advancement in Alzheimer’s care by maintaining therapeutic efficacy while enhancing patient convenience and safety.

This innovation reduces systemic adverse events, lessens the logistical burden of IV infusions, and introduces the possibility of at-home administration, potentially improving adherence and quality of life.

As Alzheimer’s management progresses toward individualized, multi-target approaches, facilitating varied and patient-friendly delivery systems such as subcutaneous injection constitutes a crucial step in expanding therapeutic options across diverse patient populations.

Ongoing research will clarify how this modality integrates with evolving combination therapies, but the current data provide a robust foundation to support broader use of lecanemab in early-stage AD.

References

1. Swanson CJ et al. “Phase 3 Trials of Lecanemab in Early Alzheimer’s Disease.” NEJM. 2023;388(1):29-41. doi:10.1056/NEJMoa2212527.

2. Knopman DS, et al. “Amyloid-Related Imaging Abnormalities in Anti-Amyloid Treatments.” Alzheimer’s Research & Therapy. 2022;14(1):88.

3. Alzheimer’s Drug Discovery Foundation Statement on Lecanemab Subcutaneous Approval, 2024. Available from: https://www.alzdiscovery.org/article/latest-research/lecanemab-sq-approval.

4. U.S. Food and Drug Administration. “FDA Approves Subcutaneous Lecanemab for Alzheimer’s Disease Maintenance Therapy,” 2024. Available at: https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-sq-lecanemab.